Can erdafitinib treat liver cancer? Applicable cancer types and efficacy analysis

Erdafitinib is a targeted drug that is mainly used to treat cancers with FGFR (fibroblast growth factor receptor) gene mutations, especially urothelial carcinoma with FGFR mutations. Despite the positive results of erdafitinib in the treatment of urothelial cancer, there is currently insufficient evidence that it is effective in the treatment of liver cancer. Erdafitinib mainly prevents tumor growth by inhibiting the FGFR pathway, so its therapeutic scope is mainly focused on cancer types related to abnormalities in the FGFR pathway.

Liver cancer, especially hepatocellular carcinoma (HCC), is usually caused by a variety of factors, including chronic hepatitis, cirrhosis, etc. Although erdafitinib has shown certain efficacy in the treatment of cancers related to FGFR mutations, its application in the treatment of liver cancer is still in the exploratory stage. Current research focuses on the relationship between FGFR mutations and liver cancer, but clinical data are limited. Some studies have shown that abnormal activation of the FGFR pathway may exist in liver cancer. Therefore, in theory, erdafitinib may have an effect on certain types of liver cancer, especially when patients with liver cancer have FGFR mutations.

Currently, erdafitinib has been approved for use in urothelial cancer and has shown good therapeutic effects. Clinical trials have shown that erdafitinib can effectively inhibit tumor growth and improve the survival rate of patients with urothelial cancer with FGFR mutations. Compared with other traditional chemotherapy drugs, erdafitinib has a more precise targeting effect and has relatively mild side effects. Therefore, erdafitinib has been considered a powerful therapeutic option in the treatment of tumors associated with FGFR pathway abnormalities, especially urothelial carcinoma.

Although erdafitinib is not currently approved for the treatment of liver cancer, as more clinical studies are conducted, especially for patients with liver cancer with FGFR mutations, its potential application in liver cancer may be discovered in the future. Although the current evidence is insufficient, erdafitinib may show some efficacy in some specific liver cancer subtypes. Therefore, for patients with liver cancer, especially those with FGFR gene mutations, erdafitinib may become a treatment option worth considering in the future.

Reference link:https://www.balversa.com/